Tesamorelin
MetabolicGHRH-analog metabolic research peptide.
Description
Tesamorelin is a stabilized analog of growth hormone-releasing hormone (GHRH), supplied as a lyophilized powder for in-vitro research. It is studied in laboratory models of the GHRH receptor and lipid/metabolic signaling. Sold strictly for research use, not for human or veterinary use.
Storage & handling
Store lyophilized vials at -20 °C, protected from light and moisture. Keep sealed until use and avoid repeated freeze–thaw cycles. Handle per your laboratory's standard operating procedures.
Research applications
- GHRH-receptor binding and signaling assays
- Lipid- and metabolic-pathway research
- Analytical reference standard
Sold strictly for in-vitro laboratory research. Not for human or veterinary use, diagnosis, treatment, or consumption.
Research status
Where the published evidence stands for each active compound, with the primary source. Regulatory standing is listed for context only. Nothing sold here is approved for human use.
- TesamorelinFDA-approved, separate indication
Approved by the FDA in 2010 as Egrifta for HIV-associated lipodystrophy, on the basis of two Phase 3 trials. That authorization covers only that indication and that finished drug product.
PubMed 21115997 · FDA approval
Researchers also viewed
“Purity matched the label exactly. Mass spec and HPLC both checked out. Reordering.”
Research associate, Raleigh, NC